Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UTI antibiotics Rx-to-OTC switch would not be cost effective -- epidemiology study.

This article was originally published in The Tan Sheet

Executive Summary

UTI ANTIBIOTICS Rx-TO-OTC SWITCH WOULD NOT BE COST-EFFECTIVE in the long term, Betsy Foxman, PhD, University of Michigan School of Public Health, and Nicole Rubin of the Sausalito, Calif.-based Lewin Group, assert in the November Journal of Clinical Epidemiology. OTC sale of antibiotics for urinary tract infections would lead to additional treatment costs of "more than $300 mil." over a 20-year period as well as increased resistance to the drugs resulting from their expanded availability, according the authors' cost-effectiveness analysis conducted under a grant from the National Institute of Diabetes & Digestive & Kidney Diseases.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086469

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel